0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Tratamiento de la insuficiencia cardiaca con vasodilatadores

      Cardiology

      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          La introducción en el armamentario terapéutico de los agentes vasodilatadores ofrece una nueva perspectiva en el tratamiento de la insuficiencia cardiaca. Al reducir la impedancia aórtica y/o al disminuir el retorno venoso al corazón, los vasodilatadores reducen la tension sistólica del ventriculo izquierdo (postcarga). De este modo, estos fármacos aumentan el Easto cardiaco al abatir las resistencias arterioiares sistémicas y reducen la presión de llenado del ventriculo izquierdo al disminuir el tono venoso. La selección del vasodilatador que debe usarse en cada caso depende del efecto particular delfármaco y del patron hemodinámico presente. Esta novedosa forma de tratamiento no excluye sino que complementa a los metodos convencionales de tratamiento tales como los digitálicos y los diuréticos.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-1557-3
          978-3-318-01519-5
          0008-6312
          1421-9751
          1980
          1980
          07 November 2008
          : 66
          : Suppl 2
          : 146-153
          Affiliations
          Instituto Nacional de Cardiología “Dr. Ignacio Chávez”, México, D.F., México
          Article
          173021 Cardiology 1980;66:146–153
          10.1159/000173021
          7285025
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Prazosin en Enfermedad Cardiaca

          General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology

          Comments

          Comment on this article